{"filing":{"accession_number":"0001493152-26-041832","cik":"0001290877","ticker":null,"company_name":"Clinuvel Pharmaceuticals Ltd","form":"6-K","filing_date":"2026-09-08","report_date":"2026-09-08","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1290877/000149315226041832/form6-k.htm"},"events":[{"id":32127,"run_id":29515,"accession_number":"0001493152-26-041832","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"CLINUVEL announced completion of development of ZEROKIN™, a proprietary single-use administration device for subcutaneous drug delivery, with IP application submitted and plans to pursue FDA 510(k) registration and CE marking. This is a material operational and strategic milestone—a new product/technology platform—but does not fit the specific event categories (not an earnings release, M\u0026A, executive change, impairment, or litigation). The disclosure reflects significant R\u0026D progress and commercial strategy advancement that would affect investor assessment of the company's pipeline and competitive positioning.","company_name":"Clinuvel Pharmaceuticals Ltd","ticker":null,"filing_date":"2026-09-08","form":"6-K","submitted_at":null,"items":[{"id":35219,"accession_number":"0001493152-26-041832","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CLINUVEL announced completion of development of ZEROKIN™, a proprietary single-use administration device for subcutaneous drug delivery, with IP application submitted and plans to pursue FDA 510(k) registration and CE marking. This is a material operational and strategic milestone—a new product/technology platform—but does not fit the specific event categories (not an earnings release, M\u0026A, executive change, impairment, or litigation). The disclosure reflects significant R\u0026D progress and commercial strategy advancement that would affect investor assessment of the company's pipeline and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T10:06:00.768939+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35219,"accession_number":"0001493152-26-041832","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CLINUVEL announced completion of development of ZEROKIN™, a proprietary single-use administration device for subcutaneous drug delivery, with IP application submitted and plans to pursue FDA 510(k) registration and CE marking. This is a material operational and strategic milestone—a new product/technology platform—but does not fit the specific event categories (not an earnings release, M\u0026A, executive change, impairment, or litigation). The disclosure reflects significant R\u0026D progress and commercial strategy advancement that would affect investor assessment of the company's pipeline and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-09T10:06:00.768939+00:00","company_name":"Clinuvel Pharmaceuticals Ltd","ticker":null,"filing_date":"2026-09-08"}]}